Hanlim & Korean Government Fund Pathway to Clinical Trial
Filed with ASX · · 3 pages · English
Summary by 6ix AI
Invion Ltd. has announced the securing of non-dilutive funding from Hanlim Pharm and the Korean Government for its preclinical program targeting oesophageal cancer. This initiative addresses a significant medical need in a market projected to grow substantially due to poor survival rates associated with oesophageal cancer.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Invion
- Invion Secures Expanded Photosoft Global Exclusive License
- Appendix 4C and Quarterly Activities Report - September 2025
- Funded Collaboration Agreement with Protect Animal Health
- Repayment of Lind Facility with Successful Capital Raise
- Response to ASX Aware Letter
Later from Invion
- Pause in Trading
- Trading Halt
- Major Shareholders Lead Invion $1.3M Capital Raise
- Appendix 4C and Quarterly Activities Report - December 2025
- Appendix 4D and Half Year Financial Report
Follow Invion into a list and get an email when it puts out news.
Follow Invion